AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.
Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the treatment Synagis in the United States.
The move is a significant commercial boost for rare diseases specialist Sobi, giving it a substantially increased U.S. footprint and expanding its business in immunology, and its shares jumped more than 6 percent.
“The addition of Synagis will become an important catalyst for Sobi’s future development and will form a powerful platform for growth in rare diseases,” said Chief Executive Guido Oelkers.
For AstraZeneca, whose stock gained 0.7 percent, it marks another step to streamline operations as it turns increasingly to a new batch of drugs – notably against cancer – to drive future growth.
Just last week AstraZeneca sold three older drugs for asthma and rhinitis to a small Swiss company for at least $350 million.
Sobi also gets the right to participate in AstraZeneca’s share of U.S. profits and losses in a follow-on drug for respiratory syncytial virus, called MEDI8897, which AstraZeneca is developing with Sanofi, the companies said.
AstraZeneca will receive $1 billion in cash and $500 million in Sobi shares, equal to a stake of 8 percent in the Swedish group.
The British drugmaker is also entitled to further contingent payments. It will get up to $470 million in sales-related payments for Synagis, a $175 million milestone when MEDI8897 is filed for U.S. approval, and other potential payments related to the new drug of up to $170 million.
By Ben Hirschler
Source: Reuters
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
